As FDA continues to assess its response to last year's H1N1 pandemic, a top agency official said this week that FDA should examine its approach to foster the development of adaptable technologies. The position is mirrored in a new HHS medical countermeasures enterprise report, which recommends that FDA consider use of new, multi-use manufacturing facilities; develop at least three flu vaccine candidates that don't rely on virus grown in eggs or cells; and lead an HHS-wide effort to review new regulatory and legal approaches for adding products to the stockpile.